BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at

Publication date: Jun 25, 2025

Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. It is characterized by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain critical for motor control. Parkinsons Disease. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). The active agent is approved in the U. S. and in about 40 countries for related complications of advanced liver cirrhosis. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Both neuroinflammation and insulin resistance are drivers of AD and PD.

Concepts Keywords
Americans Al
Immunosuppressive Alzheimers
Insulin Bezisterim
Morning Biovie
Clinical
Disease
Drug
Insulin
June
Motor
Parkinsons
Pd
Phase
Symptoms
Trial

Semantics

Type Source Name
drug DRUGBANK Nevirapine
disease MESH neurodegenerative disorders
disease MESH liver disease
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Dopamine
disease MESH tremors
disease MESH muscle rigidity
disease MESH cognitive impairment
disease MESH mood disorders
disease MESH facial expressions
drug DRUGBANK Isoxaflutole
drug DRUGBANK Levodopa
disease MESH complications
disease MESH dyskinesia
disease MESH inflammation
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease MESH Neuroinflammation
disease MESH oxidative stress
pathway REACTOME Glucose metabolism
disease MESH disease progression
disease MESH drug interaction
disease MESH long COVID
drug DRUGBANK Carbidopa
disease MESH neurological disorders
disease MESH brain fog
drug DRUGBANK Terlipressin
disease MESH liver cirrhosis
disease MESH ascites
drug DRUGBANK Coenzyme M
pathway REACTOME Release

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *